US President Barack Obama signed the Drug Quality and Security Act into the statue books last week, charging the Food and Drug Administration (FDA) with the development of track and trace system and setting out how the agency should oversee compounding pharmacies.
Industry group PhRMA was one of the first to welcome the new law explaining that, among other things, it will mean individual US States do not develop their own supply chain monitoring systems. The new laws were also seen as good news by Europe-based contract manufacturing organisation Recipharm, which in-Pharmatechnologist.com visited last week.
Supply chain security consortium, Rx360, is the latest to embrace the new legislation.
The organisation whose members include staff from drugmakers Pfizer, Amgen, GSK, Merck KGaA said in a post on its Linkedin group the law “will protect consumers and improve security in the pharmaceutical supply chain. Everyone benefits from the steps taken in this legislation to prevent counterfeit and contraband from reaching patients.”